Katalin Dobra
Papers
1
Total Citations
35
H-Index
1
About
Katalin Dobra is a leading researcher in malignant mesothelioma, a rare and aggressive cancer with limited treatment options. Her work centers on understanding tumor biology and improving therapeutic strategies through personalized medicine. A key contribution is her 2014 study, which established a method for characterizing and profiling drug sensitivity in primary malignant mesothelioma cells derived from pleural effusions. This ex vivo chemosensitivity assay addresses a critical clinical challenge: only 40% of patients respond to standard first-line pemetrexed and platinum-based chemotherapy. By enabling the prediction of the most effective drug regimen for individual patients, Dobra’s research bridges the gap between laboratory science and clinical practice. Her work has garnered significant attention, with this foundational paper accumulating 35 citations, reflecting its impact on the field. Dobra’s achievements highlight her commitment to translating molecular insights into actionable tools, offering hope for improved outcomes in mesothelioma care. Her research continues to inspire advances in precision oncology and tumor-specific drug testing.
Research Focus
Key Achievements
Top Papers
- 1